Intelligence Profile
Clinical Applications
Tralesinidase Alfa is being investigated for its potential use in treating Sanfilippo Syndrome Type B, also known as Mucopolysaccharidosis Type IIIB (MPS IIIB). This condition is a lysosomal storage disorder caused by a deficiency of the enzyme alpha-N-acetylglucosaminidase, leading to the accumulation of heparan sulfate. This accumulation results in progressive neurological damage.
Evidence from Studies:
Animal Studies:
- A study involving juvenile cynomolgus monkeys demonstrated the safety, pharmacokinetics, and central nervous system (CNS) distribution of Tralesinidase Alfa administered via intracerebroventricular infusion, a method aimed at optimizing enzyme delivery to the brain (PMID: 36923444).
- In a canine model of MPS IIIB, Tralesinidase Alfa enzyme replacement therapy was shown to prevent disease manifestations, suggesting effectiveness in mitigating the progression of the disease (PMID: 35717448).
Human Trials:
- A Phase I/II study on intracerebroventricular administration of Tralesinidase Alfa in patients with Sanfilippo Syndrome Type B indicated a potential for therapeutic benefit, particularly in addressing neurological symptoms (PMID: 36413418).
Clinical Trials:
- A Phase III clinical trial (NCT07579910) is in the planning stages, with the aim of further evaluating the effectiveness and safety of this treatment in MPS IIIB patients.
- An early access program (NCT07733856) is available, allowing patients with MPS IIIB to receive treatment with Tralesinidase Alfa outside of clinical trials.
Overall, the preliminary studies and current trials suggest that Tralesinidase Alfa could offer a significant treatment option for Sanfilippo Syndrome Type B by delivering the deficient enzyme directly to the CNS, potentially slowing or preventing neurological decline.
Disclaimer: This information is based on current research and is not intended as medical advice. For personalized medical guidance, please consult a healthcare provider.